228 related articles for article (PubMed ID: 24574717)
21. Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes.
Shi F; Wu M; Lian SS; Mo ZQ; Gou Q; Xu RD; Li HL; Huang ZM; Wu PH; Chen XM
Radiology; 2019 Dec; 293(3):707-715. PubMed ID: 31638492
[TBL] [Abstract][Full Text] [Related]
22. Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization Therapy Versus Surgical Resection for Hepatocellular Carcinoma within the Milan Criteria: A Meta-Analysis.
Wang WD; Zhang LH; Ni JY; Jiang XY; Chen D; Chen YT; Sun HL; Luo JH; Xu LF
Korean J Radiol; 2018; 19(4):613-622. PubMed ID: 29962868
[TBL] [Abstract][Full Text] [Related]
23. Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.
Welker MW; Zangos S; Kriener S; Mönch C; Zeuzem S; Trojan J
J Gastrointest Cancer; 2010 Jun; 41(2):149-52. PubMed ID: 20396977
[TBL] [Abstract][Full Text] [Related]
24. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes.
Hyun D; Cho SK; Shin SW; Park KB; Lee SY; Park HS; Do YS
Acta Radiol; 2018 Jul; 59(7):773-781. PubMed ID: 29034691
[TBL] [Abstract][Full Text] [Related]
25. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone.
Kim JW; Kim JH; Won HJ; Shin YM; Yoon HK; Sung KB; Kim PN
Eur J Radiol; 2012 Mar; 81(3):e189-93. PubMed ID: 21353417
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation.
Wang X; Liang H; Lu Z
Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044
[No Abstract] [Full Text] [Related]
27. Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
Kudo M; Arizumi T
Oncology; 2017; 93 Suppl 1():127-134. PubMed ID: 29258086
[TBL] [Abstract][Full Text] [Related]
28. Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chembolization for the Treatment of Hepatocellular Carcinoma.
Thornton LM; Cabrera R; Kapp M; Lazarowicz M; Vogel JD; Toskich BB
Curr Probl Diagn Radiol; 2017; 46(6):402-409. PubMed ID: 28392205
[TBL] [Abstract][Full Text] [Related]
29. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller.
Kim JW; Kim JH; Sung KB; Ko HK; Shin JH; Kim PN; Choi HK; Ko GY; Yoon HK; Chun SY; Gwon DI
Am J Gastroenterol; 2014 Aug; 109(8):1234-40. PubMed ID: 24935276
[TBL] [Abstract][Full Text] [Related]
30. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
Yan S; Xu D; Sun B
Dig Dis Sci; 2013 Jul; 58(7):2107-13. PubMed ID: 23361576
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.
Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y
Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995
[TBL] [Abstract][Full Text] [Related]
32. Viable hepatocellular carcinoma around retained iodized oil after transarterial chemoembolization: radiofrequency ablation of viable tumor plus retained iodized oil versus viable tumor alone.
Kim JH; Kim PN; Won HJ; Shin YM
AJR Am J Roentgenol; 2014 Nov; 203(5):1127-31. PubMed ID: 25341154
[TBL] [Abstract][Full Text] [Related]
33. Emerging targeted strategies in advanced hepatocellular carcinoma.
Finn RS
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
[TBL] [Abstract][Full Text] [Related]
34. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
Zhu K; Huang J; Lai L; Huang W; Cai M; Zhou J; Guo Y; Chen J
Radiology; 2018 Jul; 288(1):300-307. PubMed ID: 29688153
[TBL] [Abstract][Full Text] [Related]
35. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma.
Georgiades CS; Hong K; Geschwind JF
Cancer J; 2008; 14(2):117-22. PubMed ID: 18391617
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
37. Transarterial Chemoembolization Monotherapy in Combination with Radiofrequency Ablation or Percutaneous Ethanol Injection for Hepatocellular Carcinoma.
Xu C; Lv PH; Huang XE; Wang SX; Sun L; Wang FA
Asian Pac J Cancer Prev; 2016; 17(9):4349-4352. PubMed ID: 27797242
[TBL] [Abstract][Full Text] [Related]
38. Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma.
Nouso K; Kariyama K; Nakamura S; Oonishi A; Wakuta A; Oyama A; Ako S; Dohi C; Wada N; Morimoto Y; Takeuchi Y; Kuwaki K; Onishi H; Ikeda F; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2017 Mar; 32(3):695-700. PubMed ID: 27597181
[TBL] [Abstract][Full Text] [Related]
39. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
40. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials.
Lu Z; Wen F; Guo Q; Liang H; Mao X; Sun H
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):187-94. PubMed ID: 23134976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
